These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37192651)

  • 1. The Role of CD36/GPIV in Platelet Biology.
    Bendas G; Schlesinger M
    Semin Thromb Hemost; 2024 Mar; 50(2):224-235. PubMed ID: 37192651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
    Qi Z; Hu L; Zhang J; Yang W; Liu X; Jia D; Yao Z; Chang L; Pan G; Zhong H; Luo X; Yao K; Sun A; Qian J; Ding Z; Ge J
    Circulation; 2021 Jan; 143(1):45-61. PubMed ID: 32988222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet CD36 signaling through ERK5 promotes caspase-dependent procoagulant activity and fibrin deposition in vivo.
    Yang M; Kholmukhamedov A; Schulte ML; Cooley BC; Scoggins NO; Wood JP; Cameron SJ; Morrell CN; Jobe SM; Silverstein RL
    Blood Adv; 2018 Nov; 2(21):2848-2861. PubMed ID: 30381401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.
    Magwenzi S; Woodward C; Wraith KS; Aburima A; Raslan Z; Jones H; McNeil C; Wheatcroft S; Yuldasheva N; Febbriao M; Kearney M; Naseem KM
    Blood; 2015 Apr; 125(17):2693-703. PubMed ID: 25710879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosome poly-ubiquitin inhibits platelet activation, downregulates CD36 and inhibits pro-atherothombotic cellular functions.
    Srikanthan S; Li W; Silverstein RL; McIntyre TM
    J Thromb Haemost; 2014 Nov; 12(11):1906-17. PubMed ID: 25163645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein.
    Nergiz-Unal R; Lamers MM; Van Kruchten R; Luiken JJ; Cosemans JM; Glatz JF; Kuijpers MJ; Heemskerk JW
    J Thromb Haemost; 2011 Sep; 9(9):1835-46. PubMed ID: 21696539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia.
    Yang M; Li W; Harberg C; Chen W; Yue H; Ferreira RB; Wynia-Smith SL; Carroll KS; Zielonka J; Flaumenhaft R; Silverstein RL; Smith BC
    Blood Adv; 2020 Sep; 4(18):4494-4507. PubMed ID: 32946569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin: the role of phosphodiesterase 3A.
    Berger M; Raslan Z; Aburima A; Magwenzi S; Wraith KS; Spurgeon BEJ; Hindle MS; Law R; Febbraio M; Naseem KM
    Haematologica; 2020 Mar; 105(3):808-819. PubMed ID: 31289200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD36 as a multiple-ligand signaling receptor in atherothrombosis.
    Nergiz-Unal R; Rademakers T; Cosemans JM; Heemskerk JW
    Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):42-55. PubMed ID: 20939828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD36 signaling in vascular redox stress.
    Yang M; Silverstein RL
    Free Radic Biol Med; 2019 May; 136():159-171. PubMed ID: 30825500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated glycosylation of CD36 in platelets is a risk factor for oxLDL-mediated platelet activation in type 2 diabetes.
    Agarwal S; Saha S; Ghosh R; Sarmadhikari D; Asthana S; Maiti TK; Khadgawat R; Guchhait P
    FEBS J; 2024 Jan; 291(2):376-391. PubMed ID: 37845743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein.
    Chen K; Febbraio M; Li W; Silverstein RL
    Circ Res; 2008 Jun; 102(12):1512-9. PubMed ID: 18497330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.
    Ghosh A; Li W; Febbraio M; Espinola RG; McCrae KR; Cockrell E; Silverstein RL
    J Clin Invest; 2008 May; 118(5):1934-43. PubMed ID: 18431509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions.
    Yang M; Cooley BC; Li W; Chen Y; Vasquez-Vivar J; Scoggins NO; Cameron SJ; Morrell CN; Silverstein RL
    Blood; 2017 May; 129(21):2917-2927. PubMed ID: 28336528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel role for CD36 in VLDL-enhanced platelet activation.
    Englyst NA; Taube JM; Aitman TJ; Baglin TP; Byrne CD
    Diabetes; 2003 May; 52(5):1248-55. PubMed ID: 12716760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects.
    Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Sawamura T; Gioffre WR; Auteri A; Puccetti L
    Clin Appl Thromb Hemost; 2005 Oct; 11(4):417-28. PubMed ID: 16244767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade.
    Roberts W; Magwenzi S; Aburima A; Naseem KM
    Blood; 2010 Nov; 116(20):4297-306. PubMed ID: 20664056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized low-density lipoprotein-dependent platelet-derived microvesicles trigger procoagulant effects and amplify oxidative stress.
    Wang H; Wang ZH; Kong J; Yang MY; Jiang GH; Wang XP; Zhong M; Zhang Y; Deng JT; Zhang W
    Mol Med; 2012 Mar; 18(1):159-66. PubMed ID: 22064971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microvesicle/CD36 complex triggers a prothrombotic phenotype in patients with non-valvular atrial fibrillation.
    Wang H; Song NP; Li JP; Wang ZH; Ti Y; Li YH; Zhang W; Zhong M
    J Cell Mol Med; 2020 Jul; 24(13):7331-7340. PubMed ID: 32510852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased platelet CD36 constitutes a common marker in myeloproliferative disorders.
    Thibert V; Bellucci S; Cristofari M; Gluckman E; Legrand C
    Br J Haematol; 1995 Nov; 91(3):618-24. PubMed ID: 8555064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.